X0202 4 2007-06-29 1 0000834306 BIOSITE INC BSTE 0001238913 BLICKENSTAFF KIM D BIOSITE INCORPORATED 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121 0 1 0 1 Chairman & CEO Chairman & CEO Common Stock 2007-06-29 4 U 0 76 92.5 D 0 D Incentive Stock Option (right to buy) 24.95 2007-06-29 4 D 0 4008 0 D 2012-06-18 Common Stock 4008 0 D Incentive Stock Option (right to buy) 31.625 2007-06-29 4 D 0 3162 0 D 2010-06-02 Common Stock 3162 0 D Incentive Stock Option (right to buy) 41.56 2007-06-29 4 D 0 2406 0 D 2011-06-14 Common Stock 2406 0 D Incentive Stock Option (right to buy) 44.18 2007-06-29 4 D 0 2263 0 D 2014-06-18 Common Stock 2263 0 D Incentive Stock Option (right to buy) 47.66 2007-06-29 4 D 0 2121 0 D 2013-06-18 Common Stock 2121 0 D Incentive Stock Option (right to buy) 53.38 2007-06-29 4 D 0 1873 0 D 2015-06-17 Common Stock 1873 0 D Non-Qualified Stock Option (right to buy) 24.95 2007-06-29 4 D 0 50992 0 D 2012-06-18 Common Stock 50992 0 D Non-Qualified Stock Option (right to buy) 31.625 2007-06-29 4 D 0 79649 0 D 2010-06-02 Common Stock 79649 0 D Non-Qualified Stock Option (right to buy) 41.56 2007-06-29 4 D 0 97594 0 D 2011-06-14 Common Stock 97594 0 D Non-Qualified Stock Option (right to buy) 44.18 2007-06-29 4 D 0 47737 0 D 2014-06-18 Common Stock 47737 0 D Non-Qualified Stock Option (right to buy) 47.66 2007-06-29 4 D 0 67879 0 D 2013-06-18 Common Stock 67879 0 D Non-Qualified Stock Option (right to buy) 49.15 2007-06-29 4 D 0 15000 0 D 2014-10-22 Common Stock 15000 0 D Non-Qualified Stock Option (right to buy) 53.38 2007-06-29 4 D 0 63127 0 D 2015-06-17 Common Stock 63127 0 D This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $270,740 representing the difference between the exercise price of the option and $92.50, the merger consideration ($67.55 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $192,487 representing the difference between the exercise price of the option and $92.50, the merger consideration ($60.88 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $122,562 representing the difference between the exercise price of the option and $92.50, the merger consideration ($50.94 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $109,348 representing the difference between the exercise price of the option and $92.50, the merger consideration ($48.32 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $95,106 representing the difference between the exercise price of the option and $92.50, the merger consideration ($44.84 per share). This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $73,272 representing the difference between the exercise price of the option and $92.50, the merger consideration ($39.12 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $3,444,510 representing the difference between the exercise price of the option and $92.50, the merger consideration ($67.55 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $4,848,633 representing the difference between the exercise price of the option and $92.50, the merger consideration ($60.88 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $4,971,438 representing the difference between the exercise price of the option and $92.50, the merger consideration ($50.94 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $2,306,652 representing the difference between the exercise price of the option and $92.50, the merger consideration ($48.32 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $3,043,694 representing the difference between the exercise price of the option and $92.50, the merger consideration ($44.84 per share). This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $650,250 representing the difference between the exercise price of the option and $92.50, the merger consideration ($43.35 per share). This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $2,469,528 representing the difference between the exercise price of the option and $92.50, the merger consideration ($39.12 per share). End of period holdings reflects 76 shares purchased in connection with the Company's ESPP plan on 6/28/07. By: Robyn Shutak For: Kim Blickenstaff 2007-07-02